【产品介绍】：

生物活性：Phytanic acid-d3 is the deuterium labeled Phytanic acid[1]. Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease[2][3][4][5][6].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Phytanic acid-d3 相关抗体:
BNSP Antibody
FACL4 Antibody
BrdU Antibody (YA578)
GAPDH Antibody
Glucose 6 Phosphate Dehydrogenase Antibody
METTL3 Antibody
TSG101 Antibody
Alkaline Phosphatase Antibody
Calnexin Antibody (YA573)
Lamin A/C Antibody
Lamin B1 Antibody
LAMP1 Antibody
LAMP2 Antibody (YA713)
LAMP2a Antibody
NQO1 Antibody (YA697)
NQO1 Antibody (YA261)
OPA1 Antibody
RBM3 Antibody
Synaptophysin Antibody (YA043)
Laminin beta 1 Antibody
Heme Oxygenase 1 Antibody
Ki67 Antibody (YA717)
Ki67 Antibody (YA322)
Asparagine Synthetase Antibody
Calnexin Antibody
Ki67 Antibody (YA001)
Osteopontin Antibody
Synaptophysin Antibody (YA664)
TREM2 Antibody
GAPDH Antibody (YA848)
分子量：315.55
Formula：C20H37D3O2
CAS 号：1383920-40-8
非标记 CAS：14721-66-5
性状：液体
颜色：Colorless to light yellow
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Solution, -20°C, 2 years
纯度 & 产品资料
纯度： ≥98.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Budden SS, et al. Dysmorphic syndrome with phytanic acid oxidase deficiency, abnormal very long chain fatty acids, and pipecolic acidemia: studies in four children. J Pediatr. 1986 Jan;108(1):33-9.
 [Content Brief]
[3]. McLean BN, et al. A new defect of peroxisomal function involving pristanic acid: a case report. J Neurol Neurosurg Psychiatry. 2002 Mar72(3):396-9.
 [Content Brief]
[4]. Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov44(5):720-30.
 [Content Brief]
[5]. Poll-The BT, et al. Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis. 19869(2):169-74.
 [Content Brief]
[6]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug39(35):5709-5720.
 [Content Brief]